A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma
This Study is
No Longer Enrolling
Details
Age
Adult
Eligibility
Choroidal tumor must be no greater than 2.5 mm in height and 10 mm in width and show growth over 3 months to 2 years. Must be treatment naive with no other cancer or metastatic disease.
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 20-1186
More information available at ClinicalTrials.gov: NCT04417530
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers